{ "ok": true, "cik": "1679628", "ticker": "JUNS", "name": "JUPITER NEUROSCIENCES, INC.", "filings": [ { "form": "8-K", "filed": "2026-09-03", "items": [ "5.03 Amendments to Articles or Bylaws; Change in Fiscal Year", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1679628/000149315226041315/0001493152-26-041315-index.htm" }, { "form": "8-K", "filed": "2026-08-28", "items": [ "3.01 Notice of Delisting or Failure to Satisfy a Listing Rule", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1679628/000149315226040577/0001493152-26-040577-index.htm" }, { "form": "8-K", "filed": "2026-08-27", "items": [ "1.01 Entry into a Material Definitive Agreement", "5.02 Departure or Election of Directors; Appointment of Officers", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1679628/000149315226040308/0001493152-26-040308-index.htm" }, { "form": "8-K", "filed": "2026-08-24", "items": [ "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1679628/000149315226039886/0001493152-26-039886-index.htm" }, { "form": "8-K", "filed": "2026-08-24", "items": [ "1.01 Entry into a Material Definitive Agreement", "3.02 Unregistered Sales of Equity Securities", "8.01 Other Events", "9.01 Financial Statements and Exhibits" ], "url": "https://www.sec.gov/Archives/edgar/data/1679628/000149315226039785/0001493152-26-039785-index.htm" }, { "form": "10-Q", "filed": "2026-08-14", "items": [], "url": "https://www.sec.gov/Archives/edgar/data/1679628/000149315226038463/0001493152-26-038463-index.htm" } ], "events12m": 19, "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001679628.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1679628" }, "license": "Figures as filed with the SEC. Card text CC BY 4.0, POPS4.", "notAdvice": "Reporting, not investment advice. No price targets, no buy or sell views.", "edgar": "🫧 Edgar looked up JUPITER NEUROSCIENCES, INC. ($JUNS). Last filing: 8-K (5.03 Amendments to Articles or Bylaws; Change in Fiscal Year), 2026-09-03. 19 event filings (8-K) in the past twelve months. Auditor change (8-K Item 4.01) filed 2025-04-21.", "auditor": { "changes": [ { "filed": "2025-04-21", "url": "https://www.sec.gov/Archives/edgar/data/1679628/000164117225005506/0001641172-25-005506-index.htm" } ], "nonReliance": [], "restatedSince": null }, "metrics": { "fiscalYearEnd": "2025-12-31", "revenue": 21796, "revenueGrowth1y": null, "revenueGrowthPerYear": null, "yearsOfData": 2, "operatingMargin": -408.7319232886768, "operatingMarginPrior": null, "netMargin": -396.6276839787117, "operatingCashFlow": -5413736, "capitalSpending": null, "freeCashFlow": null, "researchAndDevelopment": 2086574, "researchShareOfRevenue": 95.7319691686548, "cash": null, "longTermDebt": null, "longTermDebtChange": null, "revenueHistory": [ { "fiscalYearEnd": "2024-12-31", "revenue": 0 }, { "fiscalYearEnd": "2025-12-31", "revenue": 21796 } ], "totalEquity": -1831852, "totalAssets": 5564030, "equityRatio": -0.32923115080256576, "returnOnEquity": null, "dividendsPaid": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "priceBased": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown.", "range80": null, "ifPaceHeld": null }, "edgarette": "🔖 Exposure: revenue $22K (FY2025). Experience: one year on record; operating margin -40873.2%, up from null. Soundness: equity -32.9% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -40873.2% against a -3.8% median.", "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "summary": "Jupiter Neurosciences (JUNS) reported revenue of $0 million in FY2025, operating margin -40873% against a -3.8% median for pharmaceutical preparations, equity -32.9% of assets. Every figure is from the company’s own annual report filed with the SEC.", "chart": "
JUPITER NEUROSCIENCES, INC. against its own record and its peers
Operating marginPeer median -3.8%-40873.2%Equity of assetsPeer median 40.3%-32.9%Gold tick: the median of 118–118 peers with $50M+ revenue in pharmaceutical preparations
", "chartHorizon": null, "backtest": { "tests": 0, "hits": 0, "rate": null, "method": "v3", "note": "hindsight: past years, same calibrated range. The range was calibrated on 2022-2024 SEC data, so years in that window are partly in-sample." }, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "schema": "pops4.edgarette.card/1", "card": { "summary": "Jupiter Neurosciences (JUNS) reported revenue of $0 million in FY2025, operating margin -40873% against a -3.8% median for pharmaceutical preparations, equity -32.9% of assets. Every figure is from the company’s own annual report filed with the SEC.", "exposure": { "fiscalYearEnd": "2025-12-31", "revenue": 21796, "totalDebt": null, "cash": null }, "experience": { "revenueGrowth1y": null, "revenueGrowthPerYear": null, "operatingMargin": -408.7319232886768, "operatingMarginPrior": null, "netMargin": -396.6276839787117, "freeCashFlow": null }, "soundness": { "equityRatio": -0.32923115080256576, "returnOnEquity": null, "payoutRatio": null, "dividendPerShare": null, "dividendYearsRising": null, "dividendCut": null, "note": "Dividend yield, price/earnings and price/book need a share price. The boards carry filings only, so they are not shown." }, "peers": { "sic": 2834, "sicDescription": "Pharmaceutical Preparations", "calendarYear": 2025, "minRevenue": 50000000, "depth": 4, "group": "2834", "growth": [ 0.1365, 111 ], "opMargin": [ -0.038, 114 ], "equityRatio": [ 0.4028, 118 ], "returnOnEquity": [ -0.0112, 100 ], "payoutRatio": [ 0.403, 13 ] }, "credibility": { "auditedYears": 2, "weight": "moderate", "standard": "ASOP No. 25", "nonReliance": null, "auditorChange": { "filed": "2025-04-21", "url": "https://www.sec.gov/Archives/edgar/data/1679628/000164117225005506/0001641172-25-005506-index.htm" } }, "range": null, "caution": "Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.", "sources": { "facts": "https://data.sec.gov/api/xbrl/companyfacts/CIK0001679628.json", "filings": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1679628" } }, "definitions": { "operatingMargin": "Operating income divided by revenue.", "netMargin": "Net income divided by revenue.", "freeCashFlow": "Cash from operations minus spending on property and equipment.", "researchShareOfRevenue": "Research and development expense for the year as a share of revenue, both as filed.", "equityRatio": "Shareholders equity as a share of total assets, both as filed. Higher means less of the company is owed to someone else.", "returnOnEquity": "Net income for the year against shareholders equity at year end.", "payoutRatio": "Dividends paid as a share of net income, in the year the cash went out.", "dividendYearsRising": "Consecutive years, counted back from the last on record, in which dividend per share rose. A fall ends the run and is reported as dividendCut.", "revenueGrowthPerYear": "Compound annual growth between the first and latest fiscal years shown.", "credibility": "How much weight a record deserves, in the actuarial sense (ASOP No. 25): more audited years, more weight.", "peers": "Medians of SEC filers with $50M+ revenue in the same industry code (SIC), narrowest group with at least 8 filers, calendar-year figures from SEC XBRL frames.", "backtest": "The same if-the-pace-held arithmetic applied to the company's own past years, scored against what it actually reported next. Hindsight, and labelled so." } }